S. Ashwell

发表

DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

S. Ashwell, S. Zabludoff, 2008, Clinical Cancer Research.

Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.

J. Wendoloski, P. Lyne, S. Ashwell, 2004, Journal of medicinal chemistry.

Intramolecular functionalisation by a methylene radical of a 1,2-diol and a vicinal amino alcohol: models for coenzyme B12-dependent diol dehydratase and ethanolamine ammonia lyase

Rosaleen J. Anderson, B. Golding, S. Ashwell, 2000 .

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials

J. Janetka, S. Ashwell, Sonya Z abludoff, 2008 .

Inhibitors of checkpoint kinases: from discovery to the clinic.

P. Lyne, J. Janetka, S. Ashwell, 2007, Current opinion in drug discovery & development.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

V. Oza, P. Lyne, J. Janetka, 2008, Bioorganic & medicinal chemistry letters.

A method for quantitating nanogram amounts of soluble protein using the principle of silver binding.

S. Ashwell, G. Krystal, B. Munt, 1985, Analytical biochemistry.

The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.

D. Huryn, S. Ashwell, T. Yednock, 2004, Current topics in medicinal chemistry.

Discovery and Optimization of Quinolinone Derivatives as Potent, Selective and Orally Bioavailable mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.

Mark T. Kershaw, S. Ashwell, K. Bair, 2019, Journal of medicinal chemistry.

Strategies towards more effective anticancer therapies: targeting DNA damage response pathways

S. Ashwell, 2010, Expert review of clinical pharmacology.

Model experiments pertaining to the mechanism of action of vitamin B12-dependent α-methyleneglutarate mutase

A. G. Davies, B. Golding, S. Ashwell, 1989 .

Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor.

Mark T. Kershaw, S. Ashwell, D. Walker, 2020, Journal of medicinal chemistry.

Checkpoint Kinase and Wee1 Inhibitors as Anticancer Therapeutics

S. Ashwell, 2012 .

Caspases: recent advances in small molecule inhibitors

S. Ashwell, 2001 .

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Stephen Green, B. Caleb, G. Schwartz, 2008, Molecular Cancer Therapeutics.

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

J. Breed, V. Oza, P. Lyne, 2012, Journal of medicinal chemistry.

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.

J. Janetka, S. Ashwell, S. Zabludoff, 2008, Expert opinion on investigational drugs.

A Mechanistic Overview of B12‐dependent Processes

S. Ashwell, W. Buckel, I. Garnett, 2007 .

Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents

Gary K. Schwartz, Mithat Gönen, Demetri T. Moustakas, 2010, Cancer Chemotherapy and Pharmacology.

Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.

Jon Read, Mei Su, J. Breed, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.

J. Breed, V. Oza, P. Lyne, 2010, Bioorganic & medicinal chemistry letters.

Synthesis, characterization and evaluation of pro-drugs of VLA-4 antagonists.

D. Huryn, S. Ashwell, A. Konradi, 2004, Bioorganic & medicinal chemistry letters.

Checkpoint kinase inhibitors: a review of the patent literature

J. Janetka, S. Ashwell, James W Janetka, 2009, Expert opinion on therapeutic patents.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

B. Caleb, G. Schwartz, J. Janetka, 2008, Molecular Cancer Therapeutics.

An improved model for B12-dependent diol dehydrase

Rosaleen J. Anderson, B. Golding, S. Ashwell, 1990 .